FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis

RALEIGH, N.C., Sept. 21, 2021 -- (Healthcare Sales & Marketing Network) -- Mayne Pharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in adolescents. LEXET... Biopharmaceuticals, Dermatology, FDA Mayne Pharma, LEXETTE, halobetasol, plaque psoriasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news